Literature DB >> 25853309

Theory and practice of supersaturatable formulations for poorly soluble drugs.

Kohsaku Kawakami.   

Abstract

Candidate compounds with high activity do not always possess adequate physicochemical properties to be developed as commercial products. Notably, the development of candidates with poor aqueous solubility has been a great challenge in the past two decades. Formulations that offer supersaturated state during the dissolution process are considered effective for increasing the oral bioavailability of such candidates. Representative supersaturatable dosage forms include amorphous solid dispersions, nanocrystal formulations and self-(micro)emulsifying drug delivery systems. This review describes the characteristics of these formulations, with emphasis on the suitability of the candidates for each type of formulation, from a physicochemical viewpoint. Influence of developmental strategy on the formulation selection is also discussed. This review aims to provide guidance for selecting formulations for poorly soluble drugs based on both academic and practical backgrounds.

Mesh:

Substances:

Year:  2015        PMID: 25853309     DOI: 10.4155/tde.14.116

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  3 in total

1.  Physicochemical Properties of Solid Phospholipid Particles as a Drug Delivery Platform for Improving Oral Absorption of Poorly Soluble Drugs.

Authors:  Kohsaku Kawakami; Aoi Miyazaki; Mayuko Fukushima; Keiko Sato; Yuko Yamamura; Kohta Mohri; Shinji Sakuma
Journal:  Pharm Res       Date:  2016-11-07       Impact factor: 4.200

Review 2.  Recent advances in improving oral drug bioavailability by cocrystals.

Authors:  Shahram Emami; Mohammadreza Siahi-Shadbad; Khosro Adibkia; Mohammad Barzegar-Jalali
Journal:  Bioimpacts       Date:  2018-05-31

Review 3.  Crystallization Tendency of Pharmaceutical Glasses: Relevance to Compound Properties, Impact of Formulation Process, and Implications for Design of Amorphous Solid Dispersions.

Authors:  Kohsaku Kawakami
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.